BenevolentAI Investor Conference Presentation Deck

TM Validation of the Benevolent Platform T Target Identification with Big Pharma • Collaboration with AZ expanded from two to four disease areas • Delivered multiple novel targets into AZ's pipeline Hit Identification through to Preclinical Stage with Big Pharma . Collaboration with Merck in three therapeutic areas • Validation of our chemistry tech and lab capabilities Proven Novel Indication Expansion Leading to FDA Approval - Fast • Through our platform, identified baricitinib, a RA drug owned by Eli Lilly, as a potential COVID 19 treatment. I.e identifying novel biology through our data / algorithms • Led to FDA emergency use approval in Nov 2020 and full approval in May 2022 Internal Pipeline of Novel, Best in Class And First in Class Programmes • Demonstrates utility to find novel insights previously not connected in the literature • Develop and advance unique and differentiated molecules BenevolentAl Proprietary AstraZeneca Merck Lilly FDA BEN-8744 BEN-28010 BEN-34712 Parkinson's Fibrosis Benevolent 9

View entire presentation